natural altern - NAII

NAII

Close Chg Chg %
3.15 0.06 1.90%

Closed Market

3.21

+0.06 (1.90%)

Volume: 64.45K

Last Updated:

Feb 6, 2026, 4:00 PM EDT

Company Overview: natural altern - NAII

NAII Key Data

Open

$3.18

Day Range

3.10 - 3.69

52 Week Range

2.59 - 4.95

Market Cap

$22.79M

Shares Outstanding

6.18M

Public Float

4.88M

Beta

0.36

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.95

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

19.27K

 

NAII Performance

1 Week
 
-21.71%
 
1 Month
 
-29.61%
 
3 Months
 
8.63%
 
1 Year
 
-23.57%
 
5 Years
 
-78.95%
 

NAII Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About natural altern - NAII

Natural Alternatives International, Inc. engages in the manufacturing, distribution, and marketing of nutritional supplements and other health care products. It operates through the Private-Label Contract Manufacturing, and Patent and Trademark Licensing segments. The Private-Label Contract Manufacturing segment provides manufacturing services to companies that market and distribute nutritional supplements and other health care products. The Patent and Trademark Licensing segment is involved in direct raw material sales and royalty income from license and supply agreements associated with the sale and use of beta-alanine. The company was founded by Mark A. LeDoux in 1980 and is headquartered in Carlsbad, CA.

NAII At a Glance

Natural Alternatives International, Inc.
1535 Faraday Avenue
Carlsbad, California 92008
Phone 1-760-736-7700 Revenue 129.58M
Industry Pharmaceuticals: Other Net Income -13,575,000.00
Sector Health Technology 2025 Sales Growth 13.819%
Fiscal Year-end 06 / 2026 Employees 234
View SEC Filings

NAII Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.151
Price to Book Ratio 0.296
Price to Cash Flow Ratio 3.29
Enterprise Value to EBITDA -25.683
Enterprise Value to Sales 0.511
Total Debt to Enterprise Value 0.892

NAII Efficiency

Revenue/Employee 553,769.231
Income Per Employee -58,012.821
Receivables Turnover 8.685
Total Asset Turnover 0.767

NAII Liquidity

Current Ratio 2.058
Quick Ratio 1.194
Cash Ratio 0.428

NAII Profitability

Gross Margin 6.954
Operating Margin -5.508
Pretax Margin -8.288
Net Margin -10.476
Return on Assets -8.032
Return on Equity -17.978
Return on Total Capital -10.651
Return on Invested Capital -10.402

NAII Capital Structure

Total Debt to Total Equity 86.268
Total Debt to Total Capital 46.314
Total Debt to Total Assets 35.499
Long-Term Debt to Equity 79.791
Long-Term Debt to Total Capital 42.837
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Natural Altern - NAII

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
167.97M 157.02M 113.85M 129.58M
Sales Growth
-5.91% -6.52% -27.50% +13.82%
Cost of Goods Sold (COGS) incl D&A
147.37M 142.94M 106.93M 120.57M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
6.91M 7.08M 4.65M 4.56M
Depreciation
6.91M 7.08M 4.65M 4.56M
Amortization of Intangibles
- - - -
-
COGS Growth
-5.43% -3.01% -25.19% +12.76%
Gross Income
20.59M 14.09M 6.92M 9.01M
Gross Income Growth
-9.21% -31.61% -50.88% +30.25%
Gross Profit Margin
+12.26% +8.97% +6.08% +6.95%
2022 2023 2024 2025 5-year trend
SG&A Expense
9.72M 4.74M 15.20M 16.15M
Research & Development
2.50M 2.10M 1.90M 1.80M
Other SG&A
7.22M 2.64M 13.30M 14.35M
SGA Growth
+24.39% -51.21% +220.65% +6.25%
Other Operating Expense
- - - 1.42M
-
Unusual Expense
200.00K 200.00K 200.00K 1.80M
EBIT after Unusual Expense
10.68M 7.72M (8.48M) (8.94M)
Non Operating Income/Expense
3.06M (3.71M) (622.00K) (887.00K)
Non-Operating Interest Income
- 33.00K 176.00K 168.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
83.00K 451.00K 361.00K 915.00K
Interest Expense Growth
-29.66% +443.37% -19.96% +153.46%
Gross Interest Expense
83.00K 451.00K 361.00K 915.00K
Interest Capitalized
- - - -
-
Pretax Income
13.66M 3.56M (9.46M) (10.74M)
Pretax Income Growth
+12.65% -73.97% -366.22% -13.48%
Pretax Margin
+8.13% +2.26% -8.31% -8.29%
Income Tax
2.95M 1.03M (2.25M) 2.83M
Income Tax - Current - Domestic
1.30M 1.05M (14.00K) 3.94M
Income Tax - Current - Foreign
900.00K 221.00K 66.00K 161.00K
Income Tax - Deferred - Domestic
751.00K (242.00K) (2.23M) (1.27M)
Income Tax - Deferred - Foreign
- - - (69.00K)
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
10.71M 2.52M (7.22M) (13.57M)
Minority Interest Expense
- - - -
-
Net Income
10.71M 2.52M (7.22M) (13.57M)
Net Income Growth
-0.52% -76.46% -386.16% -88.10%
Net Margin Growth
+6.38% +1.61% -6.34% -10.48%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
10.71M 2.52M (7.22M) (13.57M)
Preferred Dividends
- - - -
-
Net Income Available to Common
10.71M 2.52M (7.22M) (13.57M)
EPS (Basic)
1.7512 0.4302 -1.2293 -2.2828
EPS (Basic) Growth
+2.31% -75.43% -385.75% -85.70%
Basic Shares Outstanding
6.12M 5.86M 5.87M 5.95M
EPS (Diluted)
1.7403 0.4291 -1.2293 -2.2828
EPS (Diluted) Growth
+3.10% -75.34% -386.48% -85.70%
Diluted Shares Outstanding
6.16M 5.88M 5.87M 5.95M
EBITDA
17.79M 15.00M (3.63M) (2.58M)
EBITDA Growth
-21.38% -15.69% -124.22% +29.06%
EBITDA Margin
+10.59% +9.55% -3.19% -1.99%

Insider Actions for Natural Altern - NAII

Date Name Shares Transaction Value
Mar 12, 2025 Mark A. LeDoux CEO/Chairman; Director 160,211 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $3.84 per share 615,210.24
Mar 12, 2025 Kenneth Eugene Wolf President, COO, & Sec. 131,994 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $3.84 per share 506,856.96
Mar 12, 2025 Alan G. Dunn Director 91,211 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Guru Ramanathan Director 30,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Laura Kay Matherly Director 34,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Michael E. Fortin Chief Financial Officer 50,873 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $3.84 per share 195,352.32

Natural Altern in the News